Skip to main content

Starling Oncology, Inc.

STLN
Exchange
Nasdaq
Industry
Services-Offices & Clinics of Doctors of Medicine
SEC CIK
0001799191

In the last 90 days, Starling Oncology, Inc. insiders filed 3 open-market purchases and 2 sales; 119 institutions reported holding it in 13F filings for Q2 2026, worth $217.6M in total; no superinvestor holds it.

Other share classesDFPHSTLNW

Q1 2023 vs. Q4 2022

How the institutions holding Starling Oncology, Inc. changed between Q4 2022 and Q1 2023.

All holders in Q1 2023All holders in Q4 2022

13F holders of STLN: Q4 2022 compared with Q1 2023
MeasureQ4 2022Q1 2023Change
Holders4039−1
Shares23.5M22.0M−1.57M (−6.7%)
Value$38.7M$14.9M−$23.9M (−61.7%)

New holders (6)

Institutions that held Starling Oncology, Inc. at the end of Q1 2023 but not at the end of Q4 2022.

Institutions new to STLN in Q1 2023
InstitutionSharesValue% of portfolio
Renaissance Technologies LLC132,500$90.0K0.00%
Jane Street Group, LLC47,127$31.9K0.00%
Susquehanna International Group, LLP44,019$29.8K0.00%
First Republic Investment Management, Inc.18,300$12.4K0.00%
SG Americas Securities, LLC14,740$10.0K0.00%
Wells Fargo & Company6,858$4.65K0.00%

Sold out (7)

Institutions that held Starling Oncology, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.

Institutions that sold out of STLN in Q1 2023
InstitutionShares, Q4 2022Value, Q4 2022
Jefferies Financial Group Inc.192,452$317.5K
Alpine Global Management, LLC46,326$76.0K
CI Private Wealth, LLC12,500$21.0K
Federated Hermes, Inc.6,697$11.1K
Citigroup Inc235$388
Credit Suisse AG1$2
Nisa Investment Advisors, LLC13$0